InflaRx N.V.
NASDAQInflaRx N.V. heads into its May 15 earnings call with three fresh analyst target raises, a $150 million equity raise, and a stock that has tripled in a month — a setup that rarely travels without tension. The catalyst driving the move is clear. InflaRx priced a $150 million underwritten share offering on May 8. Rather than punishing the dilution, the market treated it as a funding…
IFRX short interest climbed 20.1% over the past week to 2.04M shares, while stock gained 23.4% in the same period. Cost to borrow sits at 7.9% APR.
Snapshot as of 22 Jun 2026
InflaRx N.V. heads into its May 15 earnings call with three fresh analyst target raises, a $150 million equity raise, and a stock that has tripled in a month — a setup that rarely travels without tension. The catalyst…
IFRX has surged 150% in a month — and options traders are now the most defensive they've been all year ahead of Thursday's earnings. The clearest signal into this print is in the options market. The put/call ratio has…
InflaRx enters its May 7 results carrying a month-long price surge and a borrow market that has quietly loosened — a setup that puts the clinical pipeline firmly in the spotlight. The stock's 116% one-month gain to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IFRX — free to start on ORTEX.
Sign up for free →Open IFRX on ORTEX